Market Footprint BIOSerenity serves over 200 European hospitals and processes diagnostics for more than 100,000 patients annually, indicating a substantial installed base and recurring demand for connected medical devices and digital biomarkers.

Strategic Partnerships Recent collaborations with Stratusneuro and ongoing private equity investments suggest opportunities to scale EEG and neurology solutions through integrated partnerships and potential co-development deals.

Clinical Applications Focus areas in neurology, sleep disorders, and cardiology align with high-value chronic-disease monitoring needs, presenting cross-sell opportunities for multi-disease remote monitoring platforms.

Technology Enablement Leveraging IoT sensors, AI-driven digital biomarkers, and an interoperable platform creates upsell potential for advanced analytics, dashboards, and integration with existing hospital IT ecosystems.

Competitive Position With private equity funding and expansion into connected textiles for data capture, there is a path to position BIOSerenity as a end-to-end patient monitoring solution, differentiating from traditional devices and opening conversations with hospital procurement and digital health teams.